UroGen Pharma Ltd.

URGN

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 31, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
UGN-101 instillations	Phase 3	Carcinoma, Transitional Cell	-
UGN-104	Phase 3	Upper Urinary Tract Urothelial Carcinoma	-
UGN-103	Phase 3	Bladder Cancer	-
120 mg MMC in 90ml gel	Phase 2	Bladder Cancer	-
UGN-102	Phase 2	Bladder Cancer	-

Catalyst Timeline

1 upcoming, 0 past

⭐Phase 3Next

Mar 31, 2026UGN-104

Primary completion for UGN-104 trial (NCT06774131) in Upper Urinary Tract Urothelial Carcinoma

Regulatory Approvals

URGN News